Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 6/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 4/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021318 | 0.95 | NPC1 (0.40) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL22085274 | 0.93 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL6079243 | 0.93 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL6077962 | 0.93 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL27727578 | 0.93 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL6078384 | 0.93 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL5617415 | 0.93 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL755754 | 0.82 | MAP3K14 (0.39) | NPC1KDM4ECRBNMAP3K14GLA | |
| SCHEMBL20131206 | 0.81 | NPC1 (0.40) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL18888511 | 0.81 | NPC1 (0.40) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092986-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092986-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | CD22, SBDS, CD2 | NPC1 3431/4885ALDH1A1 834/4885L3MBTL1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.